Authorized purpose: MRI image enhancement through noise reduction and sharpening for clinical image review.
Clinical role
Post-processing image enhancement
Images and patients
MRI · Whole Body
Key limitation
Keep in mind: Produces enhanced images, not diagnostic findings or disease classifications. Radiologists retain responsibility for interpreting the images.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: MRI image enhancement through noise reduction and sharpening for clinical image review.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Whole Body Input: Standard-of-care or accelerated DICOM MRI, including 2D/3D, contrast and noncontrast images of all body parts across the described protocols and 0.25-3 T field strengths.
Who uses it?Intended users: Radiologists and technologists in imaging centers, clinics or hospitals.
What does the software produce?Output: Noise-reduced, sharpened DICOM images sent to a configured PACS, MR device or workstation; enhanced and original images coexist.
What is its most important limitation?Key limitation: Produces enhanced images, not diagnostic findings or disease classifications. Radiologists retain responsibility for interpreting the images.
Clinical takeaway. Clinical role: MRI image enhancement through noise reduction and sharpening for clinical image review.
Evidence takeaway. Evidence from the reviewed source record: The regulatory summary includes a 97-sample standalone comparison and a separate 410-image reader study assessing enhancement. A later vendor-authored study evaluates downstream classification using enhanced images and is contextual only.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
MRI image enhancement through noise reduction and sharpening for clinical image review.
Standard-of-care or accelerated DICOM MRI, including 2D/3D, contrast and noncontrast images of all body parts across the described protocols and 0.25-3 T field strengths.
The regulatory summary includes a 97-sample standalone comparison and a separate 410-image reader study assessing enhancement. A later vendor-authored study evaluates downstream classification using enhanced images and is contextual only.
Exact FDA submission
Checked 2026-09-05
Baseline study counts retained with separate study units; no pooled unique-patient total is asserted.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The regulatory summary includes a 97-sample standalone comparison and a separate 410-image reader study assessing enhancement. A later vendor-authored study evaluates downstream classification using enhanced images and is contextual only.
FDA source
Exact FDA submission
Checked 2026-09-05
Baseline study counts retained with separate study units; no pooled unique-patient total is asserted.
No exact-release disease-detection sensitivity is established by the reviewed enhancement studies.
Reported specificity
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-05
No exact-release disease-detection specificity is established by the reviewed enhancement studies.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Deep Learning-Based Enhancement of Already Diagnostic-Quality MRI for Alzheimer's Disease Classification: Effects on Model Performance and Training Data Requirements
DesignRetrospective downstream machine-learning classification study
Population2293 ADNI brain MRI scans split into training, validation and internal testing; 270 NACC scans for external testing, 1.5 T 3D T1 gradient echo
Scopeproduct family
Tested versionSubtleHD; software release not established in the reviewed abstract
Samplen=2293
IndependenceSponsor or vendor study
PMID:42593101 · DOI:10.1002/jmri.70507
Several authors are affiliated with Subtle Medical. ResNet34/DenseNet121, not SubtleHD itself, performed Alzheimer/MCI/normal classification. No diagnostic indication or numeric accuracy is transferred to K243250.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Standard-of-care or accelerated DICOM MRI, including 2D/3D, contrast and noncontrast images of all body parts across the described protocols and 0.25-3 T field strengths.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Background processing without an end-user image-viewing UI; configuration through files, environment settings or series descriptions. DICOM destinations are specified by AE title and IP address.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes SubtleHD as a software package with no user interface that operates on a virtual machine. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Software package Same Same Same Characteristics Operates on a virtual machine" … "As it only processes images for the end user, the device has no user interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Noise-reduced, sharpened DICOM images sent to a configured PACS, MR device or workstation; enhanced and original images coexist.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Noise-reduced, sharpened DICOM images sent to a configured PACS, MR device or workstation; enhanced and original images coexist.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes SubtleHD as a software package with no user interface that operates on a virtual machine. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software package Same Same Same Characteristics Operates on a virtual machine" … "As it only processes images for the end user, the device has no user interface.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Background processing without an end-user image-viewing UI; configuration through files, environment settings or series descriptions. DICOM destinations are specified by AE title and IP address.
Subtle Medical's current compliance page lists an annual SOC 2 Type II + HIPAA security audit, and ISO 13485:2016 (valid until 2027-07-12) and ISO/IEC 42001:2023 (valid until 2028-07-17) certificates. The page gives no audit period or report scope, and the SOC 2 report was not read.
Vendor-wide
Checked 2026-10-25
Vendor-wide statement, not an independent attestation. It does not establish certificate or report scope for this exact release, expiry, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-05Last searched
21Fields reviewed
11Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
42608377 is editorial metadata, excluded as primary performance evidence. 42593101 abstract reviewed and retained as vendor-associated family study of downstream classification; exact release unverified. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, peer reviewed literature, stored candidate metadata, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-05 - Exact FDA submission
Current marketing offers a demo and operational-benefit examples, not a verified 1.x license/implementation price.
Pricing model: Not verified - checked 2026-09-05 - Exact FDA submission
Standalone versus suite licensing and ongoing service terms require a quote.
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission
Bounded web search on 2026-10-26 (query: "SubtleHD reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-05 - Exact FDA submission
Version-specific onboarding content, competency assessment and training costs were not established.
Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission
Current clinical-quality monitoring and upgrade acceptance procedures require confirmation.
Authorized purpose: MRI image enhancement through noise reduction and sharpening; clinicians retain responsibility for final patient management decisions.
Authorized purpose: LungMaps processes one or more 2D lung MRI time series to support radiologist interpretation of ventilation and perfusion maps; it is not the sole source for diagnosis.
Authorized purpose: Vantage Fortian and Orian 1.5T produce diagnostic MR images of the head and body, including labeled noncontrast angiography, for trained technologists and physician interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.